Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary

被引:51
作者
Itamochi, H
Kigawa, J [1 ]
Akeshima, R
Sato, S
Kamazawa, S
Takahashi, M
Kanamori, Y
Suzuki, M
Ohwada, M
Terakawa, N
机构
[1] Tottori Univ, Sch Med, Dept Obstet & Gynecol, Yonago, Tottori 6838504, Japan
[2] Jichi Med Sch, Utsunomiya, Tochigi, Japan
关键词
ovarian cancer; cisplatin; resistance; multidrug resistance-associated protein gene; cell proliferation;
D O I
10.1159/000065067
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Resistance of clear cell carcinoma (CCC) of the ovary to platinum-based chemotherapy is associated with a poor prognosis. However, the mechanism underlying the resistance of CCC to platinum has not yet been understood. We conducted the present study to clarify the mechanism of cisplatin (CDDP) resistance in CCC cells. Eleven CCC and 5 serous adenocarcinoma (SAC) cell lines were used in this study. The IC50 to CDDP ranged from 1.3 to 18.0 muM for CCC cells and from 2.2 to 13.0 muM for SAC cells. There was no correlation between multidrug resistance-associated protein expression and the sensitivity to CDDP in CCC cells. In contrast, the doubling time for CCC cells was significantly longer than that for SAC cells (61.4 vs. 29.8 h). A significant reverse correlation between the S-phase fraction and the response to CDDP was observed (r = 0.647, p < 0.05). The present study suggests that the resistance of CCC to CDDP may be caused by low cell proliferation. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:349 / 353
页数:5
相关论文
共 34 条
[1]  
ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35
[2]  
ANDREWS PA, 1988, CANCER RES, V48, P68
[3]  
AURE JC, 1971, OBSTET GYNECOL, V37, P860
[4]  
BARCELLOSHOFF MH, 1990, CANCER RES, V50, P3551
[5]   Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma [J].
Bonetti, A ;
Zaninelli, M ;
Rodella, S ;
Molino, A ;
Sperotto, L ;
Piubello, Q ;
Bonetti, F ;
Nortilli, R ;
Turazza, M ;
Cetto, GL .
BREAST CANCER RESEARCH AND TREATMENT, 1996, 38 (03) :289-297
[6]  
Chevillard S, 1996, CANCER, V77, P292, DOI 10.1002/(SICI)1097-0142(19960115)77:2<292::AID-CNCR11>3.0.CO
[7]  
2-X
[8]   CONFLUENCE-DEPENDENT RESISTANCE IN HUMAN COLON CANCER-CELLS - ROLE OF REDUCED DRUG ACCUMULATION AND LOW INTRINSIC CHEMOSENSITIVITY OF RESTING CELLS [J].
DIMANCHEBOITREL, MT ;
PELLETIER, H ;
GENNE, P ;
PETIT, JM ;
LEGRIMELLEC, C ;
CANAL, P ;
ARDIET, C ;
BASTIAN, G ;
CHAUFFERT, B .
INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (05) :677-682
[9]   DETERMINANTS OF DRUG RESPONSE IN A CISPLATIN-RESISTANT HUMAN LUNG-CANCER CELL-LINE [J].
FUJIWARA, Y ;
SUGIMOTO, Y ;
KASAHARA, K ;
BUNGO, M ;
YAMAKIDO, M ;
TEW, KD ;
SAIJO, N .
JAPANESE JOURNAL OF CANCER RESEARCH, 1990, 81 (05) :527-535
[10]   HIGH-RESISTANCE TO CISPLATIN IN HUMAN OVARIAN-CANCER CELL-LINES IS ASSOCIATED WITH MARKED INCREASE OF GLUTATHIONE SYNTHESIS [J].
GODWIN, AK ;
MEISTER, A ;
ODWYER, PJ ;
HUANG, CS ;
HAMILTON, TC ;
ANDERSON, ME .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (07) :3070-3074